SINCE Hench and his co-workers1 described the dramatic effect of cortisone and pituitary adrenocorticotropic hormone, or ACTH, on patients with rheumatoid arthritis, interest in the effect of these substances on the "mesenchymal diseases" has mounted. Independent reports by Boland and Headley in Los Angeles,2 Thorn in Boston3 and Ragan and co-workers in New York4 amply confirmed that there are beneficial effects observed in rheumatoid patients. Only scattered reports from Hench,1 Thorn,3 Grace5 and others6 to the time of writing indicated beneficial results from this therapy in other members of the group of connective tissue disorders which includes rheumatic fever, scleroderma, dermatomyositis, periarteritis nodosa and disseminated lupus erythematosus.
This report deals with 3 patients with disseminated lupus, erythematosus, observed on the medical service of the Presbyterian Hospital, who were treated with ACTH. Experimental work conducted in an effort to explain
PLOTZ CM, BLUNT JW, RAGAN C. EFFECT OF PITUITARY ADRENOCORTICOTROPIC HORMONE (ACTH) ON DISSEMINATED LUPUS ERYTHEMATOSUS. Arch Derm Syphilol. 1950;61(6):913–918. doi:10.1001/archderm.1950.01530130031008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: